Recent research finds out how air pollution can trigger lung cancer
... of people with lung cancer. While in people who have never smoked and other genes associated with lung cancer called KRAS. This claim is ...
Improving Outcomes in Non-Small Cell Lung Cancer: Future Directions in Care
I think about some of the approaches people have used in, say,
EGFR
-mutant lung cancer. We’re trying to explore ways to improve outcomes ...
Particulate matter in air pollution may cause lung cancer in never smokers
... promoting NSCLC in at-risk epithelium harbouring driver mutations, PM increased tumour burden in three EGFR or KRAS driven lung cancer ...
Particulate make any difference in air pollution can bring about lung most cancers in nonsmokers
... NSCLC in at-hazard epithelia harboring driver mutations, PM dose-dependently enhanced tumor stress in three EGFR- or KRAS-pushed lung cancer ...
U.S. FDA panel votes against Spectrum's lung cancer drug
... is intended to treat non-small cell lung cancer (NSCLC) with a rare genetic mutation that affects 2-4% of total patients with NSCLC.
There ...
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
... in treatment-naive patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) (Presentation 1008P)
GuardantINFORM
Real-world ...
Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMO
... in locally advanced or metastatic EGFR mutated non-small cell lung cancer after progression on a 3rd-generation EGFR TKI
T. Mok
1195TiP ...
Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO
... (SCLC). EGFR mutation is common in NSCLC. About 4–12% of all EGFR mutations are insertions at exon 20 (EGFR exon20ins). Patients with EGFR ...
Latest Research at ESMO Congress 2022 Showcases the Impact of Comprehensive Genomic Profiling for Cancer Patients
... -cell lung cancer (NSCLC), it is critical to have biomarker testing results early. The results showed that 42% of stage IV NSCLC patients ...